- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Lee Schwartzberg, MD, FACP: Nurse Education on Biosimilars
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses the need for practice-wide education concerning biosimilars in cancer care.
Transcript
There has to be a practice-wide campaign for everyone in the care chain to understand biosimilars. So, when it comes to infusion nurses, they understand they're giving a different drug, but it's in the same class. And so, when we're changing drugs, we get an informed consent for these patients so they know it's a new drug. When we're starting new, the infusion nurses are just hanging them just like any other drug.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
